Hualan Biological Vaccine Inc. (SHE:301207)
16.91
+0.49 (2.98%)
Jul 10, 2026, 3:05 PM CST
Hualan Biological Vaccine Revenue
Hualan Biological Vaccine had revenue of 26.78M CNY in the quarter ending March 31, 2026, with 10.27% growth. This brings the company's revenue in the last twelve months to 1.20B, up 7.79% year-over-year. In the year 2025, Hualan Biological Vaccine had annual revenue of 1.20B with 6.62% growth.
Revenue (ttm)
1.20B
Revenue Growth
+7.79%
P/S Ratio
8.35
Revenue / Employee
1.70M
Employees
708
Market Cap
10.06B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20B | 74.69M | 6.62% |
| Dec 31, 2024 | 1.13B | -1.28B | -53.21% |
| Dec 31, 2023 | 2.41B | 584.79M | 32.03% |
| Jan 1, 2023 | 1.83B | -4.17M | -0.23% |
| Jan 1, 2022 | 1.83B | -596.52M | -24.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.87B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.93B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Nanjing Vazyme Biotech | 1.41B |
| Chengdu Easton Biopharmaceuticals | 1.35B |
| Jiangxi Fushine Pharmaceutical | 1.31B |
| Shanghai Medicilon | 1.26B |